Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M.
GlobalData on MSN4d
Four regimens fail endpoints simultaneously in HEALEY ALS trialALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the ...
Medpage Today on MSN5d
Two Investigational Treatments for ALS Show Glimmer of HopeThe first four treatments in a platform trial for amyotrophic lateral sclerosis (ALS) failed to reach key endpoints in phase ...
Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...
Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...
News Medical on MSN5d
ALS Drug-Testing Platform Speeds Therapeutic BreakthroughsAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ...
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), a ...
Four papers published in JAMA, JAMA Neurology and JAMA Network Open look at Amyotrophic Lateral Sclerosis (ALS) treatment results from the HEALY ALS Platform Trial. Dr Ahmad Al Khleifat, Senior ...
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback